Julie Jordan sold $18k of NGNE
Chief Medical Officer at Neurogene Inc.. 828 shares at an average of $21.89, traded Mar 26, 2026, filed Mar 30, 2026.
Score components
- +15RoleOfficer
- 0Trade size$18k at market
- 0Share of holdings soldSold 6.2% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +37.2%, 3m +67.3%, 6m +47.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001968554-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 26, 2026 | SOpen-market sale Common Stock10b5-1 | -828 | $21.89 | $18k | 12,472 | Mar 30, 2026 |
Related signals
Other insiders at Neurogene Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $173k 4,800 shares | -5% | |
| 13Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $167k 4,800 shares | -5% | |
| 16Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $300k 9,600 shares | -9% | |
| 24Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $55k 2,558 shares | -2% | |
| 28Weak | Neurogene Inc. | Rachel McMinn Chief Executive Officer | $74k 3,352 shares | -0% | |
| 26Weak | Neurogene Inc. | Stuart Cobb Chief Scientific Officer | $141k 6,797 shares | -18% | |
| 26Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $84k 4,045 shares | -4% | |
| 20Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $121k 4,800 shares | -4% | |
| 10Weak | Neurogene Inc. | Stuart Cobb Chief Scientific Officer | $103k 6,797 shares | -25% | |
| 10Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $76k 4,501 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.